Galectin Therapeutics Inc.
GALT Nasdaq
SEC CIK 1133416
Follow Galectin Therapeutics
Weekly email: filings, results
Net income
−$3.5M
+56.9% vs same quarter last year
EPS, diluted
−$0.04
+69.2% vs same quarter last year
Operating cash flow
−$2.3M
+36.1% vs same quarter last year
Operating income
−$3.4M
+19.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$30.8M |
| FY24 | −$47M |
| FY23 | −$41.1M |
| FY22 | −$38.8M |
| FY21 | −$30.5M |
| FY20 | −$23.5M |
| FY19 | −$13.3M |
| FY18 | −$13.9M |
| FY17 | −$16.2M |
| FY16 | −$21.4M |
| FY15 | −$20M |
| FY14 | −$15.8M |
| FY13 | −$12.1M |
| FY12 | −$9.7M |
| FY11 | −$10.9M |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | −$17M |
| FY14 | −$12.4M |
| FY13 | −$7.5M |
| FY12 | −$7.5M |
| FY11 | −$5.7M |